Provided by Tiger Trade Technology Pte. Ltd.

Adaptive Biotechnologies Corp

13.58
+0.08000.59%
Post-market: 13.53-0.0500-0.37%19:48 EDT
Volume:2.36M
Turnover:31.84M
Market Cap:2.09B
PE:-34.63
High:13.60
Open:13.36
Low:13.18
Close:13.50
52wk High:20.76
52wk Low:6.68
Shares:153.78M
Float Shares:117.37M
Volume Ratio:1.02
T/O Rate:2.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3922
EPS(LYR):-0.3922
ROE:-27.82%
ROA:-6.79%
PB:9.54
PE(LYR):-34.63

Loading ...

The Bull Case For Adaptive Biotechnologies (ADPT) Could Change Following New Pfizer Immune-Data Deals And Spinout Financing – Learn Why

Simply Wall St.
·
Jan 11

Assessing Adaptive Biotechnologies (ADPT) Valuation After New Pfizer Deals And Digital Biotechnologies Financing

Simply Wall St.
·
Jan 09

CEO and Chairman Chad M. Robins Reports Sale of Adaptive Biotechnologies Common Shares

Reuters
·
Jan 08

Chief People Officer Francis Lo Reports Sale of Adaptive Biotechnologies Common Shares

Reuters
·
Jan 07

Adaptive Biotechnologies to Present at J.P. Morgan Healthcare Conference

Reuters
·
Dec 31, 2025

Adaptive Biotechnologies Corp - to Retain Nearly 50% Ownership in Digital Biotechnologies - SEC Filing

THOMSON REUTERS
·
Dec 30, 2025

Adaptive Biotechnologies Affiliate Digital Biotechnologies Secures Up to $15 Million in Series A Financing

Reuters
·
Dec 30, 2025

Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer T-Cell Discovery and AI Drug Collaboration Deals

Simply Wall St.
·
Dec 23, 2025

Cathie Wood Dumps $11 Milllion Worth of Tesla Stock While Doubling Down on These Notable Crypto Plays

Benzinga
·
Dec 19, 2025

Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst

Benzinga_recent_news
·
Dec 16, 2025

Adaptive Biotechnologies Signs Two Immune Receptor Licensing Agreements with Pfizer

Reuters
·
Dec 15, 2025

Adaptive Biotechnologies Corp - Pfizer to Use Adaptive's Platform for Rheumatoid Arthritis

THOMSON REUTERS
·
Dec 15, 2025

Adaptive Biotechnologies Corp - May Receive up to $890 Mln in Milestones

THOMSON REUTERS
·
Dec 15, 2025

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements With Pfizer

THOMSON REUTERS
·
Dec 15, 2025

Adaptive Biotechnologies Corp: Specific Financial Terms of Agreement Will Not Be Disclosed

THOMSON REUTERS
·
Dec 15, 2025

Director Robert Hershberg Reports Disposal of Adaptive Biotechnologies Common Shares

Reuters
·
Dec 13, 2025

Adaptive Biotechnologies Executives Join Jefferies Fireside Chat on Minimal Residual Disease

Reuters
·
Dec 10, 2025

Adaptive Biotechnologies (ADPT): Valuation Check After ASH clonoSEQ Data Spotlight and Q3 Earnings Beat

Simply Wall St.
·
Dec 08, 2025

Adaptive Biotechnologies Highlights clonoSEQ Data Guiding Blood Cancer Treatment at ASH 2025

Reuters
·
Dec 06, 2025

Chief Scientific Officer Harlan S. Robins Reports Sale of Adaptive Biotechnologies Common Shares

Reuters
·
Dec 06, 2025